Next Article in Journal
Dual Stimuli-Responsive Multifunctional Silicon Nanocarriers for Specifically Targeting Mitochondria in Human Cancer Cells
Previous Article in Journal
Peptide-Based Vaccine against SARS-CoV-2: Peptide Antigen Discovery and Screening of Adjuvant Systems
Previous Article in Special Issue
Pharmacokinetics and Pharmacodynamics of Intranasal Solid Lipid Nanoparticles and Nanostructured Lipid Carriers for Nose-to-Brain Delivery
Article

Trehalose-Based Nucleolipids as Nanocarriers for Autophagy Modulation: An In Vitro Study

1
Univ. Bordeaux, INSERM U1212, CNRS UMR 5320, ARNA, ARN: Régulations Naturelle et Artificielle, ChemBioPharm, 146 rue Léo Saignat, F-33076 Bordeaux, France
2
Univ. Bordeaux, CNRS, IMN, UMR 5293, F-33000 Bordeaux, France
*
Author to whom correspondence should be addressed.
Deceased 13 December 2021.
These authors contributed equally to this work.
Academic Editors: Massimo Conese, Waldemar Debinski and Giuseppe Trapani
Pharmaceutics 2022, 14(4), 857; https://doi.org/10.3390/pharmaceutics14040857
Received: 21 March 2022 / Accepted: 8 April 2022 / Published: 13 April 2022
The Autophagy Lysosomal Pathway is one of the most important mechanisms for removing dysfunctional cellular components. Increasing evidence suggests that alterations in this pathway play a pathogenic role in Parkinson’s disease, making it a point of particular vulnerability. Numerous studies have proposed nanotechnologies as a promising approach for delivering active substances within the central nervous system to treat and diagnose neurodegenerative diseases. In this context, the aim was to propose the development of a new pharmaceutical technology for the treatment of neurodegenerative diseases. We designed a trehalose-based nanosystem by combining both a small natural autophagy enhancer molecule named trehalose and an amphiphilic nucleolipid conjugate. To improve nucleolipid protection and cellular uptake, these conjugates were formulated by rapid mixing in either solid lipid nanoparticles (Ø = 120.4 ± 1.4 nm) or incorporated into poly(lactic-co-glycolic acid) nanoparticles (Ø = 167.2 ± 2.4 nm). In vitro biological assays demonstrated a safe and an efficient cellular uptake associated with autophagy induction. Overall, these nucleolipid-based formulations represent a promising new pharmaceutical tool to deliver trehalose and restore the autophagy impaired function. View Full-Text
Keywords: nucleolipids; nanoparticles; PLGA; trehalose; autophagy nucleolipids; nanoparticles; PLGA; trehalose; autophagy
Show Figures

Figure 1

MDPI and ACS Style

Cunha, A.; Gaubert, A.; Verget, J.; Thiolat, M.-L.; Barthélémy, P.; Latxague, L.; Dehay, B. Trehalose-Based Nucleolipids as Nanocarriers for Autophagy Modulation: An In Vitro Study. Pharmaceutics 2022, 14, 857. https://doi.org/10.3390/pharmaceutics14040857

AMA Style

Cunha A, Gaubert A, Verget J, Thiolat M-L, Barthélémy P, Latxague L, Dehay B. Trehalose-Based Nucleolipids as Nanocarriers for Autophagy Modulation: An In Vitro Study. Pharmaceutics. 2022; 14(4):857. https://doi.org/10.3390/pharmaceutics14040857

Chicago/Turabian Style

Cunha, Anthony, Alexandra Gaubert, Julien Verget, Marie-Laure Thiolat, Philippe Barthélémy, Laurent Latxague, and Benjamin Dehay. 2022. "Trehalose-Based Nucleolipids as Nanocarriers for Autophagy Modulation: An In Vitro Study" Pharmaceutics 14, no. 4: 857. https://doi.org/10.3390/pharmaceutics14040857

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop